Literature DB >> 16169751

What is the current evidence on decision-making after referral for temporal lobe epilepsy surgery? A review of the literature.

Sabine G Uijl1, Frans S S Leijten, Jaime Parra, Johan B A M Arends, Alexander C van Huffelen, Karel G M Moons.   

Abstract

OBJECTIVES: Many patients thought to have temporal lobe epilepsy, are evaluated for surgical treatment. Decision-making in epilepsy surgery is a multidisciplinary, phased process involving complex diagnostic tests. This study reviews the literature on the value of different tests to decide on whether to operate.
METHODS: Articles were selected when based on the consensus decision whether to perform temporal lobe surgery, or on the consensus localization or lateralization of the epileptic focus. The articles were scrutinized for sources of bias as formulated in methodological guidelines for diagnostic studies (STARD).
RESULTS: Most studies did not fulfill the criteria, largely because they addressed prognostic factors in operated patients only. Ten articles met our inclusion criteria. In most articles, a single test was studied; SPECT accounted for five papers. Unbiased comparison of the results was not possible.
CONCLUSION: Surprisingly little research in epilepsy surgery has focused on the decision-making process as a whole. Future studies of the added value of consecutive tests are needed to avoid redundant testing, enable future cost-efficiency analyses, and provide guidelines for diagnostic strategies after referral for temporal lobe epilepsy surgery.

Entities:  

Mesh:

Year:  2005        PMID: 16169751     DOI: 10.1016/j.seizure.2005.08.001

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  1 in total

Review 1.  The added clinical and economic value of diagnostic testing for epilepsy surgery.

Authors:  Sebastian Hinde; Marta Soares; Jane Burch; Anthony Marson; Nerys Woolacott; Stephen Palmer
Journal:  Epilepsy Res       Date:  2014-02-19       Impact factor: 3.045

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.